Telix Pharmaceuticals Ltd ADR(TLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:27 PM ET (Korea 10/31 05:27)
Full metrics table
| Index | - | P/E | 97.33 | EPS (ttm) | 0.09 | Insider Own | - | Shs Outstand | 334.1M | Perf Week | -0.55% |
| Market Cap | 3.10B | Forward P/E | 199.69 | EPS next Y | -45.84% | Insider Trans | - | Shs Float | - | Perf Month | -15.11% |
| Enterprise Value | 3.42B | PEG | - | EPS next Q | 0.06 | Inst Own | 0.98% | Short Float | - | Perf Quarter | -9.18% |
| Income | 0.03B | P/S | 3.47 | EPS this Y | 498.77% | Inst Trans | 0.29% | Short Ratio | 1.12 | Perf Half Y | -19.18% |
| Sales | 0.89B | P/B | 6.34 | EPS next 5Y | - | ROA | 2.63% | Short Interest | 0.35M | Perf YTD | 21.5% |
| Book/sh | 1.44 | P/C | 12.29 | EPS past 3/5Y | 55.05% 29.38% | ROE | 7.39% | 52W High | -30.59% ($13.11) | Perf Year | -15.19% |
| Cash/sh | 0.74 | P/FCF | - | Sales past 3/5Y | 93.54% 195.21% | ROIC | 3.2% | 52W Low | 44.9% ($6.28) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 112.37 | EPS Y/Y TTM | 198.49% | Gross Margin | 52.13% | Volatility(W/M) | 1.78% 1.79% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 3.83 | Sales Y/Y TTM | 33.78% | Oper. Margin | -0.81% | ATR (14) | 0.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.85 | EPS Q/Q | - | Profit Margin | 3.76% | RSI (14) | 35.21 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.01 | Sales Q/Q | - | SMA20 | -11.49% ($10.28) | Beta | -0.15 | Target Price | $17.93 |
| Payout | - | Debt/Eq | 1.19 | Earnings | 2026/8/19 | SMA50 | -17.68% ($11.05) | Rel Volume | 1.09 | Prev Close | $9.51 |
| Employees | 1184 | LT Debt/Eq | 1.16 | EPS/Sales Surpr. | 140.27% -0.55% | SMA200 | -8.13% ($9.91) | Avg Volume(3M) | 0.31M | Price | $9.1 |
| IPO | 2024/11/14 | Option/Short | No/Yes | Trades | 2110 | Volume | 341,703 | Change | -4.31% |
☢️ This is an Australia-based biopharmaceutical company that develops and sells radiopharmaceuticals. It commercializes and sells radiopharmaceuticals for cancer diagnostics, including prostate cancer, and develops radiopharmaceuticals for cancer treatment, giving it exposure to demand for radiopharmaceuticals. The company operates in the radiopharmaceutical sector.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded about as much as usual. That is 109% of its average volume.
TLX has a sound balance sheet but weak earning power
Of every $100 in sales, $0.81 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +498.8% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $9,733. Peers typically go for $1,345.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 1.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #72 of 597 in the industry
Based on market cap of $3B.
ELVN#70 Enliven Therapeutics Inc $3B PER - 
DYN#71 Dyne Therapeutics Inc $3B PER - TLX#72 Telix Pharmaceuticals Ltd ADR $3B PER 97.3 
IDYA#73 Ideaya Biosciences Inc $3B PER - 
DNLI#74 Denali Therapeutics Inc $3B PER - 
FAQ
What kind of company is TLX?
TLX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TLX?
The market cap of TLX is approximately $3.1B, ranking 1,731 within its sector.
What is the P/E ratio of TLX?
TLX has a P/E ratio of approximately 97.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TLX?
TLX has recorded a 52-week high of $13.11 and a low of $6.28.
